DNA vaccines are an appealing strategy for inducing cytotoxic T-lymphocyte and antibody responses against tumor cells as well as infectious agents. Dendritic cells (DCs) play a critical role in inducing immune responses, but their potential is not fully utilized in the DNA vaccine setting since they take up only a minor fraction of the injected DNA. Here we describe a novel DNA vaccination strategy based on the targeting of a modified tumor-associated antigen, the human papilloma virus (HPV) type 16 E7 protein, to DCs by a heat-shock protein (HSP) to enhance antigen presentation and immune responses. Specifically, a chimerical HPV-E7 and HSP70 fusion gene preceded with a leader sequence was constructed. When mice were immunized with this construct, the DNA is taken up by various types of cells, which then produce and secrete an HPV-E7-HSP70 fusion protein that is targeted to DCs by the HSP70 portion of the chimerical molecule for antigen presentation. In studies to test the efficacy of this strategy, we demonstrated that DNA vaccination with this secretory HPV-E7-HSP70 construct strongly enhanced an antigen-specific CD8 þ T-cell response as well as a specific B-cell response in mice. Furthermore, this immunization approach not only protected mice against lethal challenge with an HPV E7-expressing tumor line (TC-1), but also showed a therapeutic effect against established tumors. The results of this study indicate that secretory HSPs can be broadly used to target tumorassociated antigens to DCs to enhance antigen-specific immune responses. Gene Therapy (2004) 11, 924-932.
Introduction
DNA vaccination is an attractive strategy in experimental immunization against viral or tumor antigens. Despite extensive efforts, the translation of DNA vaccines into clinical settings has been hampered by their limited potency. After intramuscular (i.m.) or intradermal (i.d.) injection of plasmid DNA, myocytes 1 and keratinocytes 2 appear to be the predominantly transfected cell types, but they lack the necessary costimulatory molecules to prime immune responses. However, only few bone marrow-derived antigen-presenting cells (APCs), 3, 4 especially dendritic cells (DCs) that perform a critical step in the induction of primary immune responses, are directly transfected by injected DNA, 5, 6 leading to deficient presentation of peptides from endogenously synthesized antigens on major histocompatibility complex (MHC) molecules. Studies of stably transfected myoblasts, [7] [8] [9] reconstitution of SCID mice with allogeneic bone marrow-derived APCs after DNA vaccination, 4 and surgical ablation of the injection site, 10 as well as skin excision/grafting experiments 11 also indicate a role for transfected myocytes and keratinocytes in DNA-initiated immune responses. However, these studies demonstrate that acquisition of antigens released from transfected myocytes or keratinocytes and cross-presentation by DCs are essential to induce T-cell responses for any DNA vaccination strategy. A recent study 12 indicates the involvement of heat-shock protein (HSP) 70 in these cross-priming events.
Increasing evidence shows that several HSPs, including HSP70, are highly effective and versatile molecules in potentiating immune responses via interaction with several surface receptors on APCs. HSP70 has been reported to activate the innate immune response, resulting in the maturation of DCs, [13] [14] [15] the upregulation of proinflammatory cytokines [13] [14] [15] [16] and nitric oxide release by APCs. 17 Rapid intracellular Ca 2 þ flux 18 and CD14-dependent toll-like receptor (TLR) 2-and TLR4-mediated activation of the MyD88/interleukin-1 receptor associated kinase (IRAK)/nuclear factor (NF)-kappaB signal transduction pathway 18, 19 have been reported as consequences of HSP70 binding to cell surface receptors on APCs. However, this has been the matter of some debate since recent reports 20, 21 could not confirm these observations. A receptor-mediated process has also been demonstrated for HSP70-mediated antigen cross-presentation. [22] [23] [24] [25] When administered exogenously to APCs, the peptides transported by HSPs are very efficiently presented by MHC class I molecules. Peptides complexed to HSPs in vitro, [26] [27] [28] as well as HSP-peptide complexes purified from cells expressing viral proteins 29, 30 or tumor cells, [31] [32] [33] [34] [35] induce specific CTL responses. Finally, recombinant HSP-antigen fusion proteins 36, 37 were able to elicit CD4 þ -independent CD8 þ cytotoxic T-lymphocyte (CTL) responses. [38] [39] [40] In the present study, we sought to enhance the potency of DNA vaccines by using HSP70 as a DC-targeting molecule to enhance antigen cross-presentation and DC maturation. This novel strategy (Figure 1a ) uses the human papilloma virus type-16 E7 oncoprotein (HPV16 E7) as a model antigen and HSP70 as a DC binding domain. A leader peptide was exploited to re-route the HPV-E7-HSP fusion protein into the endoplasmic reticulum for secretion. The secreted fusion protein is targeted to and then captured by DCs via the interaction of HSP70 with its cell surface receptors, bringing the antigen into the MHC class I cross-presentation pathway. The results of this study demonstrate the feasibility of this approach, illustrating its ability to enhance the CTL response and antitumor activity in mice. Our data show that this strategy does indeed lead to enhanced crosspresentation of E7 antigen by DCs.
Materials and methods

DNA constructs
All constructs were cloned into the pRc/CMV vector (Invitrogen, Carlsbad, CA, USA), with a gene placed under the control of the CMV promoter and in front of the BGH-polyA site (Figure 1b) 0 . The tyrosinase fragment was then digested with HindIII and AflII and the HSP70 PCR product was digested with AflII and XbaI. Both parts were ligated into a HindIII/XbaIdigested vector in a three-piece ligation. For the generation of pCMV-Sig/E7/HSP70, the Sig/E7 fragment was subcloned from the plasmid pCMV-sE7-Fc with 5 0 -TTTAAGCTTGCCACCATGCTCCTGGCTGTTTTGTA-3 as a forward primer and 5 0 -TTAATTCTTAAGTGGTTT CTGAGAACAGATGG-3 0 as a reverse primer. After digestion with HindIII and AflII, this fragment was ligated with the above-described AflII-XbaI HSP70 fragment into a HindIII/XbaI-digested vector in a threepiece ligation. All constructs were validated by restriction enzyme digestion and DNA sequencing. DNA for injection and in vitro transfection of mammalian cells was prepared with EndoFree Kits from Qiagen Inc. (Valencia, CA, USA).
Mice and cell lines
Female C57BL/6 mice were purchased from Harlan Sprague-Dawley Inc. (Indianapolis, IN, USA) and the Jackson Laboratory (Bar Harbor, ME, USA). CD4 and CD8 knockout mice were obtained from Jackson. TC-1 cells were a gift from TC Wu. TC-1 cells had been generated by cotransfection of primary C57BL/6 lung epithelial cells with activated ras and the HPV16 oncogenes E6 and E7. 41 These cells were grown in RPMI1640 supplemented with 10% FBS, nonessential amino acids (NEAA), L-glutamine, Na-pyruvate and 
Transfections and immunoprecipitations
293A cells were grown to about 70% confluence in 6-well plates and transfected with 1 mg plasmid DNA using Lipofectamine Plus (Invitrogen, Carlsbad, CA, USA). At 48 h after transfection, cells were labeled overnight with 35 S. Culture medium and cell lysates were immunoprecipitated either with anti-HSP70 antibody (SPA810, Stressgen Biotechnologies, Victoria, Canada) and a mixture of Protein A and Protein G or with anti-HPV16 E7 antibody (TVG710Y, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and Protein A only. The washed precipitates were resuspended in SDS-sample buffer and subjected to separation by SDS-PAGE. Bands were detected by autoradiography.
Immunizations
Endotoxin-free DNA was prepared with a Qiagen Kit, resuspended in endotoxin-free PBS (Sigma-Aldrich Corp., St Louis, MO, USA) at a final concentration of 1 mg/ml and stored at À201C until used for injection. On the day of injection, mice were shaved on their backs and 100 mg of DNA was injected intradermally in four or five small fractions. Alternatively, mice were injected i.m. into the M. quadriceps with 50 mg DNA on each side. These injections were repeated after 2 weeks.
Proliferation assays
At 2 weeks after the second vaccination, splenocytes from four mice were pooled and restimulated with the E7 peptide amino acids (aa) 49-57 42 at 2 mg/ml for 6 days, followed by restimulation with the E7 peptide and irradiated syngeneic splenocytes for 2 more days. Proliferation was then measured by incorporation of [ 
ELISPOT assays
MAIPS4510 plates (Millipore, Bedford, MA, USA) were coated overnight with the rat anti-mouse IFNg antibody AN18 (Mabtech AB, Nacka, Sweden) at 10 mg/ml, the antibody was then washed off, and the plates were blocked with R10. Serial dilutions of freshly explanted splenocytes, starting with 3 Â 10 5 cells/well were transferred to the ELISPOT plate and incubated with the E7 peptide aa 49-57 for 17 h. The cells were then washed off, and biotinylated R4-6A2 (1 mg/ml; Mabtech AB, Nacka, Sweden) was used as a secondary antibody. Avidin-HRP (Vector Labs, Burlingame, CA, USA) and AEC (SigmaAldrich Corp., St Louis, MO, USA) were used to detect IFN-g spots. Then plates were sent to ZellNet (ZellNet Consulting Inc., NY, USA) for automatic counting.
Flow cytometry
Splenocytes from immunized mice were pooled and restimulated ex vivo with peptide. An hour later, Brefeldin A was added for another 5-6 h. Cell surface markers were stained with PerCP-conjugated CD3e antibody (145-2C11; BD Pharmingen, San Diego, CA, USA) and FITC-conjugated CD8a (53-6.7; BD Pharmingen, San Diego, CA, USA) or CD4 antibody (H129.19; BD Pharmingen, San Diego, CA, USA). Intracellular cytokines were stained with PE-conjugated IFN-g (XMG1.2; BD Pharmingen, San Diego, CA, USA) or IL-4 (11B11, BD Pharmingen, San Diego, CA, USA) antibody after permeabilization and fixing of the cells with the Cytofix/Cytoperm Kit (BD Pharmingen, San Diego, CA, USA).
Recombinant E7 protein production
The primers 5 0 -GATATACATATGCATGGAGATACACC TAC-3 0 and 5 0 -TTTGCGGCCGCTGGTTTCTGAGAACA GATGGGG-3 0 were used to PCR-amplify the E7 gene and clone it in frame with the C-terminal 6-His-tag into pET21a (NdeI/NotI digested; Novagen, Madison, WI, USA), which contains an IPTG-inducible T7 promoter. This plasmid (pET21-E7) was transfected into the E. coli expression strain BL-21(DE3) (Novagen, Madison, WI, USA). After induction with 1 mM IPTG at 371C for 3 h, cells were disrupted by sonication in a buffer containing a nonionic detergent and lysozyme. pE7 was further purified over a His-binding Ni-NTA resin (Qiagen Inc., Valencia, CA, USA) and then dialyzed against PBS. The purity of this protein preparation was about 90%, as determined by Coomassie staining. The identity of the purified protein was verified by Western blotting with a monoclonal mouse antibody (TVG710Y; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA).
ELISA for serum E7 antibody
Anti-E7 antibodies in the sera of immunized mice were identified by ELISA. Microtiter plates (Dynex Technologies, Chantily, VA, USA) were coated with recombinant E7 protein at 10 mg/ml in bicarbonate buffer, pH 9.6. After blocking, sera were serially diluted in blocking buffer and incubated on the plate for 2 h at 371C. Bound antibody was detected with peroxidase-conjugated goat anti-mouse IgG antibody (Sigma-Aldrich Corp., St Louis, MO, USA). Monoclonal mouse anti-E7 antibody (TVG710Y, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) was used as a positive control.
Tumor mouse model study
To test the ability of DNA vaccination to protect mice against tumor challenge, C57BL/6 mice were immunized twice bi-weekly. At 2 weeks after the second immunization, they were injected s.c. in the right flank with either 2.5 Â 10 4 or 5 Â 10 4 TC-1 cells in PBS. In earlier experiments, 2.5 Â 10 4 tumor cells had been found sufficient to establish tumor growth in 100% of nonvaccinated mice. The mice were examined twice a week for tumor growth, with calipers used to measure tumor diameters. To test the ability of DNA vaccination to inhibit the growth of established tumor, C57BL/6 mice were first injected s.c. in the right flank with 2.5 Â 10 4 TC-1 cells. On days 3 and 10 after tumor inoculation, the mice were vaccinated intradermally with 100 mg of plasmid DNA and then monitored twice a week for tumor growth.
Results
Cloning and characterization of the secreted E7-HSP70 molecule Plasmid DNA constructs under control of the CMV promoter ( Figure 1b) were generated as described in Materials and methods. To target the E7/HSP70 fusion protein for secretion, we added the first 23 aa of the tyrosinase gene to the N-terminus of the E7 protein as Vaccination with pCMV-Sig/E7/HSP70 strongly enhances E7-specific CD8 þ T-cell-mediated immune responses
We first asked whether DNA vaccination with pCMVSig/E7/HSP70 can induce a specific immune response in vivo. C57BL/6 mice were vaccinated twice with 100 mg of pCMV-Sig/E7/HSP70, pCMV-Sig/HSP70 or pCMV-E7 plasmid DNA. At 2 weeks after the second immunization, mice were killed and splenocytes from each group were pooled. Initially, we tested whether splenocytes from vaccinated mice would respond to antigenic stimulation. The results of a proliferation assay of splenocytes stimulated with the MHC class I-restricted peptide E7 aa 49-57 are shown in Figure 2a . Only the splenocytes from mice immunized with pCMV-Sig/E7/ HSP70 actively proliferated. To further characterize the immune response, we performed intracellular cytokine staining and ELISPOT assays. Figure 2b shows a representative experiment in which we analyzed the CD8 þ restricted immune response by intracellular cytokine staining for IFN-g secreted by freshly isolated splenocytes (restimulated with the E7 peptide aa 49-57) at 2 weeks after the second DNA vaccination. Vaccination with pCMV-Sig/E7/HSP70 generated the highest frequency of E7-specific CD8 þ /IFN-g þ double-positive Tcell precursors (119 positive cells/10 5 splenocytes or 2.7% of CD8 þ cells). By contrast, the number of such precursors in mice vaccinated with pCMV-E7 or the pCMV-Sig/HSP70 control construct did not exceed background levels (for both constructs, six positive cells/10 5 splenocytes, or 0.1% of CD8 þ cells). The CD8 þ /IFN-g þ double-positive cells were confirmed to be predominantly CD8 þ T cells by costaining for CD3. ELISPOT assays also showed higher numbers of Tcell precursors specific for the MHC class I-restricted peptide E7 aa 49-57 in the mice immunized with pCMVSig/E7/HSP70 than those in the mice immunized with pCMV-Sig/HSP70 or pCMV-E7 (Po0.01) (Figure 2c) . Similar results were obtained in either i.m. or i.d. vaccinated mice.
We further tested if the sE7/HSP70 fusion proteins can be secreted from transfected cells and captured by nontransfected DCs to stimulate T cells. 293T cells were transfected with pCMV-Sig/E7/HSP70 or pCMV-E7 DNA and 48 h later, the culture media of these transfected cells were harvested. DCs were isolated from naïve C576/B6 mice by using CD11c (N418) microbeads (Miltenyi Biotec, Germany) and were pulsed with the supernatant of the transfected cells in the presence of mIL-4 (100 U/ml) and mGM-CSF (20 ng/ml). The DCs were then used as APCs to test their ability to stimulate primed T cells from pCMV-Sig/E7/HSP70-immunized mice. As shown in Figure 2d , the DCs cocultured with the supernatant of pCMV-Sig/E7/HSP70-transfected cells were more potent to stimulate primed T cells from pCMV-Sig/HSP70 immunized mice than DCs cocultured with pCMV-E7-transfected cells. This result suggests that the secretory E7-HSP from the transfected cells was more efficiently taken up by DCs.
In agreement with the intracellular staining and ELISPOT, CTL assays showed that splenocytes of the mice immunized with pCMV-Sig/E7/HSP70 were more cytotoxic to E7 þ TC-1 target cells than those in the mice immunized with pCMV-Sig/HSP70 or pCMV-E7 (Po0.01) (Figure 3) . We also sought to determine the magnitude and cytokine profile of an E7-specific CD4 þ T-cell response. Splenocytes from i.m. or i.d. vaccinated mice were restimulated in vitro with E7 peptide (aa 44-60) containing a major T-helper epitope of HPV16 E7 43 and stained for CD4 and IFN-g or IL-4 followed by flow cytometric analyses. MiCK-2 cells (BD Pharmingen, San Diego, CA, USA) secreting IL-4 were used as positive controls for cytokine staining. Despite repeated attempts, we were unable to detect an appreciable number of CD4 þ /IFN-g þ or CD4 þ /IL-4 þ double-positive cells from mice immunized with pCMV-Sig/E7/HSP70 or pCMV-E7 (data not shown). Although we cannot entirely rule out a CD4 þ response against the human E7 in this mouse model, a recent study also reported a CD4 þ independent CD8 þ T-cell response in mice immunized with recombinant mycobacterial or murine HSP70 fusion proteins. 39 Vaccination with pCMV-Sig/E7/HSP70 induces an E7-specific antibody response
Since vaccination with pCMV-Sig/E7/HSP70 should lead to the secretion of the E7/HSP70 fusion protein, we predicted that it would induce a stronger antibody response. Therefore, mice were bled 2 weeks after the second DNA vaccination, and serum antibody titers were determined by ELISA against recombinant HPV16 E7 protein.
As shown in Figure 4 , only mice vaccinated with pCMV-Sig/E7/HSP70 had a robust antibody response (Po0.01), indicating that secreted E7/HSP70 fusion proteins stimulate both T-cell and B-cell responses.
Vaccination with pCMV-Sig/E7/HSP70 protects mice against the growth of TC-1 tumor A critical test of the pCMV-Sig/E7/HSP70 DNA vaccine was its protective capacity against E7-expressing tumors in mice. Thus, in vivo tumor protection experiments were performed with the E7-expressing cell line TC-1 in syngeneic C57BL/6 mice. At 2 weeks after i.d. or i.m. (data not shown) DNA vaccination with the various constructs, mice were challenged s.c. with TC-1 cells. All mice vaccinated with pCMV-Sig/E7/HSP70 remained tumor-free for more than 120 days after TC-1 challenge, whereas all mice injected with plasmids containing the wild-type E7 gene or Sig/HSP70, as well as mice mock injected with PBS, developed tumors within 3 weeks Mice vaccinated with pCMV-Sig/E7/HSP70 showed strikingly reduced tumor growth compared to that in mice treated with pCMV-E7 or pCMV-Sig/HSP70 DNA (Po0.05) (Figure 6 ). Thus, only DNA vaccination with the pCMV-Sig/E7/HSP70 construct showed a therapeutic effect against established tumors in vivo. (d) CD11C þ DCs isolated from naïve C57BL/6 mice were pulsed with the culture media of 293 cells transfected with pCMV-Sig/E7/HSP70 or pCMV-E7 DNA in the presence of mIL-4 (100 U/ml) and mGM-CSF (20 ng/ml). The DCs as APCs were then cocultured with splenocytes (400 000 cells/ well) from pCMV-Sig/E7/HSP70-or pCMV-sig/HSP70 (control)-immunized mice at an effector:APC ratio of 20:1 for IFN-g ELISPOT assay. There is a significant difference in the number of IFN-g-producing cells between DCs-pulsed with pCMV-Sig/E7/HSP70-transfected cell medium and DCs-pulsed with pCMV-E7-transfected cell medium (Po0.05). Data show the mean and the s.d. of spot numbers from triplicate wells from one experiment that is representative of two experiments performed.
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CD8 þ T cells are essential for the antitumor effect
We further tested whether CD8 þ or CD4 þ T-cell responses are required for antitumor effects in our mouse model. Thus, we performed tumor challenge experiments with CD4-and CD8-knockout mice, as well as wild-type mice. All animals were vaccinated twice i.m. with pCMV-Sig/E7/HSP70 or other construct, and challenged with 2.5 Â 10 4 TC-1 cells 2 weeks later. Figure  7 shows the results of a representative experiment in which vaccination with pCMV-Sig/E7/HSP70 did not protect CD8-knockouts against subsequent challenge with TC-1 cells. All mice lacking CD8 þ T cells developed tumors within 2 weeks after tumor challenge, while wild-type mice or mice lacking CD4 þ T cells were largely protected. This result demonstrates that the CD8 þ T-cell response observed by ELISPOT and intracellular cytokine staining was indeed crucial for the antitumor effects seen in vivo.
Discussion
DCs perform critical functions associated with the induction and modulation of antitumor immune responses after DNA vaccination. Thus, direct transfection of DCs with DNA is one way to promote antigen presentation by these APCs. However, only a small fraction of DCs show evidence of such transfection after DNA injection. As reported here, we modified an oncoprotein in a manner that permitted it to be efficiently secreted and captured by DCs via a receptor-mediated internalization process for antigen presentation. Our results demonstrate that DNA vaccination with pCMVSig/E7/HSP70 strongly enhances the anti-E7 immune response and antitumor effect. 
HSP70-mediated antigen targeting for DNA vaccines H Hauser et al
Extensive evidence for the existence of a receptor mediated cross-presentation pathway for HSP70-antigen complexes has been published. [22] [23] [24] [25] 44 Earlier reports suggested that CD91 acts as a receptor for HSP70-mediated cross-presentation. [22] [23] [24] [25] However, recent work by Becker et al 44 identified CD40 as an extracellular receptor for binding and uptake of HSP70-peptide complexes. Taking into account the distribution of these receptors, it is obvious that, regardless of which of these receptors is responsible for HSP70-mediated cross-presentation, it is very likely that other APCs in addition to DCs also contribute to the augmentation of vaccine potency.
The pCMV-Sig/E7/HSP70 DNA vaccine appeared to induce a CD8 þ T-cell response exclusively, as no E7-specific CD4 þ T cells were detectable by standard assays. These findings are consistent with data in earlier reports of recombinant HSP70 fusion proteins that included HIV-1 p24, 36 OVA, 37,39 influenza virus NP, 45 or HPV16 E7 38 as model antigens or E7/HSP70 fusion proteins released from dying cells. 46, 47 However, it remains a mystery why the HSP-mediated presentation of E7 antigens did not induce CD4 þ T-helper responses, presumably through the receptor-mediated class II antigen presentation pathway. It has also been reported that gd T cells can recognize HSP70 on heat-treated autologous tumor cells. 48 In the setting of our vaccination (i.m. and i.d.), we can rule out a significant contribution of HSP70 activated gd T cells to the observed antitumor effect, since mice vaccinated with the Sig/HSP70 control construct did not show any protection. However, whether gd T cells or NK cells are activated to any extent by pCMV-Sig/E7/HSP70 vaccines will require further investigation. Importantly, we detected a strong E7-specific antibody response in animals vaccinated with pCMV-Sig/E7/HSP70, in contrast to earlier reports on cytoplasmic E7/HSP70 constructs, in which vaccinated mice lacked antibody responses altogether. 38 Perhaps this antibody response is further evidence of physiologically relevant secretion of fusion protein after DNA vaccination. Even though antibody-mediated immune responses have not been shown to play an important role in controlling HPV16-associated malignancies, they may be effective against other tumors, such as the experimental HER2/Neu breast cancer model. For example, by fusing the secreted extracellular domain of HER2/Neu to HSP70, it may be possible to generate a breast cancer vaccine that induces both antibody and CTL responses.
HSPs have been used to enhance the potency of DNA vaccines by others, 46, 47, 49, 50 but there are several important differences between their strategy and ours. The E7/ HSP70 fusion protein in the present report is designed to be secreted by transfected cells and targeted to DCs, as compared to cytoplasmic expression of transfected cells in previous systems. This feature provides an active mechanism to allow the fusion protein to be captured by DCs for antigen presentation regardless of the transfected cell type, or the vector system used. We are currently investigating the differences in the immune responses elicited by these different vaccination strategies.
Safety is one of the most important considerations in the development of DNA vaccines. To our knowledge, this is the first report of a genetic vaccine using human HSP70 in mice. HSPs are not only functional but also structurally highly conserved from prokaryotic to higher eukaryotic organisms. 51 A potential safety concern arises from the existence of T-lymphocytes crossreactive with myobacterial and human HSP70 52 and the demonstration of intestinal inflammation due to the transfer of HSP60-reactive CD8 þ T cells into mice. 53 Although we cannot discount this risk entirely, we believe that in a clinical setting the use of a human gene will reduce the risk of autoimmunity due to crossreactive T-lymphocytes primed by the HSP vaccine. Another safety consideration entails certain properties of the E7 antigen itself. HPV16 E7 is a nuclear oncoprotein that binds the tumor suppressor gene Rb, 54 leading to its proteasomal Figure 7 Tumor challenge experiment with CD4-and CD8-knockout mice. C57BL/6 wild-type mice, and CD4-knockout (CD4 KO) and CD8-knockout (CD8 KO) mice (five mice per group) were vaccinated twice i.m. with 100 mg of plasmid DNA and then challenged s.c. with 2.5 Â 10 4 TC-1 tumor cells and examined for tumor growth every 3 days (Po0.05, versus CD4 KO or wild-type mouse group).
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H Hauser et al degradation. 55 Since the high levels of E7 expression by DNA vaccine constructs might promote the malignant transformation of host cells, our secretion strategy would be advantageous in this regard. That is, targeting the E7 antigen into the endoplasmic reticulum for secretionand thereby preventing it from reaching the nucleusshould greatly reduce any risk associated with nuclear binding of Rb. An added safety measure might be gained by mutating the Rb-binding site, as reported by Smahel et al. 56 In summary, our data show that fusion of a secreted tumor antigen to HSP70 for antigen targeting to DCs generates a greatly improved DNA vaccine compared to the vaccines that encode the antigen only. This concept should apply equally well to antigens other than the E7 oncoprotein, and to other forms of tumor vaccines, such as those mediated by viral vectors. The further study is underway to determine the effect of secretory antigen-HSP fusion molecules in comparison with secretory antigens on DC maturation and antigen presentation in vitro and in vivo.
